Triple-Negative Breast Cancer: Understanding Subtypes and How They Guide Treatment

Table of Contents

• Key Points
• Background: Why This Research Matters
• What Is Triple-Negative Breast Cancer?
• The Many Faces of TNBC: Histological Heterogeneity
• Molecular Heterogeneity: Gene Expression Subtyping
• Genomic Characterisation and Multi-Omic Analyses
• Surrogate Classification: Making Subtyping Practical
• Treatment Implications by Subtype
• Clinical Implications: What This Means for Patients
• Limitations: What This Review Couldn't Prove
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• TNBC is not one disease; it includes distinct histological, molecular, and immune subtypes with different outcomes.
• Four major molecular subtypes are BL1, BL2, mesenchymal, and luminal androgen receptor, each with distinct treatment implications.
• Basal-like tumors respond well to chemotherapy, while LAR tumors are more chemotherapy-resistant and may need targeted approaches.
• Immunohistochemical surrogates using AR, CD8, FOXC1, and DCLK1 can identify subtypes in routine labs.
• Low-grade TNBC variants like adenoid cystic carcinoma generally have a favorable prognosis, so not all TNBCs are aggressive.

Background: Why This Research Matters

Breast cancer was among the first types of cancer for which targeted therapy became routine. In everyday clinical practice, breast tumours are classified by whether they express three key proteins: oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This classification directly guides treatment decisions.

Luminal breast cancers (those positive for ER and/or PR) can be managed with hormonal therapy. HER2-positive cancers can be treated with anti-HER2 drugs. But 10–15% of breast cancers lack all three markers—they are "triple-negative"—which means these targeted options simply don't apply.

TNBC is known for its aggressive behaviour. It tends to be higher grade, larger at diagnosis, and associated with a poorer prognosis. It also affects younger patients more often than other breast cancer subtypes. Chemotherapy has been the mainstay of systemic treatment, and while many patients respond well initially, a significant proportion eventually experience relapse. These relapses remain a major challenge in breast cancer management.

This review, written by Dr. Julia Y. Tsang and Professor Gary M. Tse from the Department of Anatomical and Cellular Pathology at The Chinese University of Hong Kong, summarizes the latest research on TNBC heterogeneity—from microscopic appearance to molecular genetics to the immune environment—and explains how recognizing these differences leads to better, more personalized treatment.

What Is Triple-Negative Breast Cancer?

Triple-negative breast cancer gets its name from what it's missing. Unlike other breast cancers, TNBC cells do not produce oestrogen receptors, progesterone receptors, or HER2. That means the standard targeted treatments for breast cancer—hormone-blocking pills and HER2-targeted antibodies—cannot help these patients.

In the era of precision medicine, researchers are identifying a growing number of "driver" genetic changes (genomic aberrations) that cause cancer growth, and matching them with targeted drugs. These developments are especially promising for TNBC. Additionally, new therapies that target the immune tumour microenvironment (TME)—the surrounding cells and tissues that support or fight the tumour—have changed how several cancers are treated, including TNBC.

The authors emphasize that TNBC is vastly heterogeneous, meaning it encompasses many different diseases with diverse profiles. While most TNBCs are high-grade and aggressive, several distinct low-grade, good-prognosis subtypes also exist. Recognizing this heterogeneity allows a more tailored treatment approach, maximising clinical benefit while minimising unnecessary side effects.

The Many Faces of TNBC: Histological Heterogeneity

Under the microscope, the vast majority of TNBCs are high-grade invasive breast cancers of no special type (IBC-NST). Some, however, show medullary features—including pushing borders, marked nuclear pleomorphism (variation in cell nucleus size and shape), numerous mitoses (dividing cells), geographic necrosis (dead tissue areas), and dense stromal lymphocytic infiltrates (immune cells invading the tumour).

Other distinct histological variants include those with apocrine differentiation and metaplastic breast carcinomas. Apocrine-differentiated tumours contain characteristic large cells with abundant eosinophilic granular cytoplasm (pink-staining grainy fluid inside the cell) and enlarged nuclei with prominent nucleoli. Metaplastic carcinomas include high-grade tumours with squamous (skin-like) or spindle cell (sarcomatoid) morphology, as well as low-grade tumours of adenosquamous type or fibromatosis-like metaplastic carcinoma.

The low-grade TNBCs fall into two main subsets:

• Salivary gland-like tumours: This group includes adenoid cystic carcinoma (AdCC), mucoepidermoid carcinoma, adenomyoepithelioma, and secretory carcinoma. They share structural and genetic features with their salivary gland counterparts.
• Acinic cell carcinoma group: Acinic cell carcinoma—characterised by clear and granular epithelial cells arranged in mainly microglandular patterns—along with microglandular adenosis (MGA) and atypical microglandular adenosis (AMGA). MGA and AMGA are considered precursor lesions with the potential to progress to high-grade TNBCs. They can exist alongside invasive tumours and mirror the complex genomic landscape of adjacent conventional TNBCs.

The uncommon tall-cell carcinoma with reverse polarity (TCCRP) also belongs to the low-grade TNBC category.

Genetic Features of Each Histological Type

Each morphological variant is underpinned by specific genetic alterations, as shown in Table 1 of the original review:

• IBC-NST: TP53 mutations and MYC gain in more than 70% of cases; PI3K pathway alterations in about 10%.
• IBC-NST with medullary pattern: Similar genomic features to IBC-NST.
• Apocrine differentiation: Similar to IBC-NST but with more PI3K pathway alterations and fewer TP53 mutations and MYC gains.
• Metaplastic breast carcinomas: Similar to IBC-NST but with more alterations in PI3K and Wnt signalling pathways, plus RAS-MAP kinase aberrations.
• Adenoid cystic carcinoma: MYB::NFIB fusion gene, MYBL1 rearrangements, or MYB amplification.
• Mucoepidermoid carcinoma: MAML2 rearrangements.
• Malignant adenomyoepithelioma: PI3K pathway and HRAS Q61 alterations.
• Secretory carcinoma: ETV6::NTRK3 fusion or ETV6 rearrangements.
• Acinic cell carcinoma and MGA/AMGA-associated cancer: Similar genomic features to IBC-NST TNBC.
• Adenosquamous and fibromatosis-like metaplastic carcinoma: PI3K pathway alterations but lacking TP53 mutations.
• Tall cell carcinoma with reverse polarity: IDH2 R172 hot-spot mutation.

These morphological variants display different clinical behaviours. In particular, the low-grade variants generally have a favourable prognosis. Recognising the histological variants is critically important because it avoids a one-size-fits-all approach to TNBC management.

Molecular Heterogeneity: Gene Expression Subtyping

Beyond what's visible under a microscope, TNBC also shows diverse genomic profiles. In the seminal breast cancer molecular classification studies, basal-like breast cancer (BLBC) was consistently found to resemble basal/myoepithelial cells and to show activation of proliferation pathways. These tumours demonstrate high expression of the epidermal growth factor receptor (EGFR) and a high frequency of germline BRCA1 (gBRCA) and TP53 mutations. Clinically and pathologically, they are high-grade with a poor prognosis.

Because BLBC features overlap considerably with TNBC, TNBCs were commonly classified into the basal-like group. However, subsequent studies showed that 20–30% of TNBCs are actually non-BLBC by gene profiling. This happens because TNBC is an immunohistochemical (protein expression) category while BLBC is defined by gene profiling—so total agreement between the two systems is not expected. Notably, this smaller group of non-BLBC TNBCs showed better survival, and they maintain the gene expression characteristics of their respective intrinsic subtypes.

Another intrinsic subtype identified later was claudin-low breast cancer. These tumours show low expression of cell–cell adhesion and proliferation-associated genes but are enriched in epithelial-to-mesenchymal transition (EMT) features, immune system responses, and stem cell-associated biological processes. The majority of claudin-low tumours are TNBCs with a poor prognosis, and they cluster among TNBCs with metaplastic and medullary differentiation. Rather than being an entirely separate group, claudin-low is now viewed as an additional complex phenotype that permeates various intrinsic subtypes—a continuous measure rather than a simple yes/no category.

The TNBCtype Classification: Six Subtypes

A landmark study proposed six TNBC subtypes (known as TNBCtype) based on messenger RNA (mRNA) expression using k-means clustering:

1. Basal-like 1 (BL1): Enriched with cell cycle genes and DNA damage response genes.
2. Basal-like 2 (BL2): Associated with growth factor receptor signalling genes.
3. Immunomodulatory (IM): Involved immune cell processes and immune signalling pathways.
4. Mesenchymal (MES): Expressed genes in cell differentiation pathways, EMT, and stem cell properties.
5. Mesenchymal stem-like (MSL): Similar to MES but also showed growth factor signalling, low proliferation gene rates, and low expression of claudin family genes.
6. Luminal androgen receptor (LAR): The most distinct subtype—despite being ER-negative, it shows activation of hormonally regulated pathways with high expression of the androgen receptor (AR), its downstream targets, and co-activators. LAR tumours correlate with apocrine differentiation on histology.

These six subtypes have different therapeutic implications, but their prognostic value was not consistently observed. An online tool called TNBCtype was developed for this classification. In follow-up studies, the IM and MSL subtype gene profiles were shown to come largely from tumour-infiltrating lymphocytes (TILs) and peritumoral stromal cells, respectively—not just from the tumour cells themselves.

Refining to Four Major Subtypes

When stroma was dissected from tumour tissue, cases previously classified as IM were reassigned to BL1. This led to a refinement into only four subtypes based on tumour-cell gene expression: BL1, BL2, MES, and LAR. The reported rates after this refinement were:

• BL1: 35–40% of TNBCs
• BL2: 11–20%
• MES: 20–33%
• LAR: 15–24%

Other researchers, using non-negative matrix factorisation clustering on immunohistochemically-defined TNBCs, described a similar four-subtype scheme called 4-TNBC: LAR, mesenchymal (MES), basal-like immunosuppressed (BLIS), and basal-like immune-activated (BLIA). BLIA had the best overall prognosis, while BLIS had the worst. LAR and MES overlapped with the earlier LAR and MSL tumours. The remaining TNBCtypes—BL1 and BL2—were split between BLIA and BLIS. The IM TNBCtype, which showed up-regulation of immune activation genes, fell into the BLIA subtype.

Compared to PAM50 subtyping, BLIA and BLIS were entirely BLBC, while luminal and HER2-overexpressing tumours were found in LAR. MES tumours were of PAM50 BLBC and normal-like types.

A similar four-subtype scheme was echoed by another recent study, which coined the term FUSCC subtyping, including LAR, IM, BLIS, and MES. Interestingly, there were ethnic differences in subtype distribution: Asian patients had more LAR and fewer BLIS subtypes.

Challenges in Subtyping

Accurate assignment of an individual tumour to a subtype is not always reproducible. When the same clustering strategy used for TNBCtype was applied to the TCGA and METABRIC datasets, only five TNBC groups were found instead of the original six—and a lack of reproducibility for BL2 was reported. Adding further complexity, an individual tumour can be composed of mixed subtypes, especially BL1 and MES. Single-cell RNA sequencing data suggested the possibility of a transition state between these two subtypes.

Genomic Characterisation and Multi-Omic Analyses

The underlying genomic driver events in TNBC were first described through integrative cluster analysis on the METABRIC dataset. The cluster known as IntClust 10—composed of tumours with high genomic instability—showed TP53 mutations and cis-acting alterations including chromosome 5 loss, and 8q, 10p, and 12p gains. This group encompassed mainly TNBCs. The chromosome 5 deletion was thought to be linked to alterations in DNA damage repair and cell-cycle genes.

This DNA repair impairment is reflected in TNBC's mutational signature. Among the four mutational signature subtypes in breast cancer, more than half of TNBCs were classified with the homologous recombination deficiency (HRD) mutational signature. Homologous recombination is a critical DNA repair pathway; when it's defective (as in BRCA-mutated cancers), tumours become vulnerable to certain drugs like platinum agents and PARP inhibitors.

A multi-omic approach using six different platforms provided a comprehensive molecular portrait. For the BLBC subtype, a high frequency of TP53 mutations was reported, along with oncogenic alterations in PI3K/AKT pathway genes (such as PIK3CA, AKT3, INPP4B, and PTEN) and germline BRCA1/2 mutations—though these were much less prevalent, appearing in fewer than 10% of cases. The principal altered genes in BLBC included ATM mutations, BRCA1 and BRCA2 inactivation, RB1 loss, and cyclin E1 amplification.

Genomic Features of the Four Subtypes

Specific genomic characteristics and potential drug targets were examined in the 4-TNBC subtypes:

• LAR tumours: Amplification of CCND1 and FGFR2 genes; loss of CDKN2A/B; the most distinct mutational profile with activating PIK3CA and ERBB2 mutations but lacking alterations in DNA repair and cell-cycle pathways.
• MES, BLIS, and BLIA tumours: A common MAGOHB amplification. Cell surface mucin MUC1 can be a target for LAR, while growth factor receptors can be MES subtype targets. BLIS and BLIA can be targeted through immunosuppression and STAT signalling, respectively.
• BL1 and MES subtypes: Both showed a higher level of mutations and a higher mutational signature of HRD. One study reported higher copy-number alterations in BL1, with gains/amplifications in MYC, PIK3CA, CDK6, AKT2, KRAS, EGFR1, IGF1R, CCNE1, and CDKN2A/B, and deletions in BRCA2, PTEN, MDM2, RB1, and TP53.
• MES subtype: Another study found the greatest degree of copy-number alterations here, with frequent deletions in DNA repair genes including BRCA2, components of the BAF SWI/SNF complex (SMARCAD1, ARID1A, ARID1B, KDM6A, BAP1), and beta-2-microglobulin.
• BL2 subtype: Mutations activating the MAPK pathway—though relatively infrequent—were enriched in this group.

Similar genomic alterations were reported in the FUSCC subtypes. More frequent ERBB2 mutations and CDKN2A/B loss were observed in FUSCC LAR, while the HRD mutational signature was enriched in FUSCC BLIS. A subset of BLIS cases had low HRD, and these showed a poorer prognosis than the more common high-HRD BLIS cases, with distinct genomic characteristics more likely to exhibit whole-genome doubling.

Subtype differences also extend to the epigenome—chemical modifications that turn genes on or off without changing the DNA sequence. The LAR subtype displayed the greatest amount of differentially hypermethylated CpG sites (methyl groups added to DNA), mainly located in gene promoters, consistent with the more differentiated status of luminal tumours. The MES subtype displayed the most hypomethylated CpGs but was hypermethylated in regions encompassing immune signalling, with a corresponding reduction in immune gene expression. This finding suggests that the MES subtype suppresses immune function through epigenetic mechanisms. Indeed, inhibiting the polycomb repressor complex 2 (PRC2) subunits EZH2 or EED restored MHC-I expression (a protein needed for immune recognition) in MES subtype tumour models—offering a potential therapeutic strategy.

Surrogate Classification: Making Subtyping Practical

Molecular techniques provide insightful and accurate subtyping information, but they aren't practical for everyday clinical use. The relatively simple and straightforward immunohistochemical (IHC) staining method—which detects specific proteins in tissue samples—remains the preferred technique in many laboratories. Because subtype-specific transcriptional pathways can lead to corresponding changes in protein levels, it's possible to develop an IHC-based surrogate classification for the molecular subtypes of TNBC.

Identifying Basal-Like Tumours with IHC

Early attempts focused on identifying the intrinsic basal-like subtype using IHC surrogates. Using EGFR and cytokeratin 5/6 as positive markers, basal-like breast cancer could be identified with 100% specificity and 76% sensitivity. A triple panel of CK14, EGFR, and 34βE12 achieved similar accuracy.

A comprehensive study compared 46 reported IHC markers against the BLBC gene expression profile. The best individual biomarkers were:

• INPP4B: 61% sensitivity and 99% specificity
• Nestin: 54% sensitivity and 96% specificity

Two other markers—FOXC1 and SOX10—have also been proposed. FOXC1 IHC achieved 75% sensitivity and 90% specificity, and its prognostic value was demonstrated. SOX10 achieved 70% diagnostic accuracy, compared to up to 60% for other markers.

IHC Surrogate for FUSCC Subtyping

A separate IHC surrogate has been proposed for the FUSCC subtyping, using four protein markers: AR, CD8, FOXC1, and DCLK1. The schema works like this:

1. LAR: AR-positive
2. IM: AR-negative and CD8-positive
3. BLIS: AR-negative, CD8-negative, and FOXC1-positive
4. MES: AR-negative, CD8-negative, FOXC1-negative, and DCLK1-positive

This schema showed substantial agreement with the gene expression subtypes. The highest agreement was found for LAR (kappa = 0.821, indicating excellent concordance), while the lowest was in MES. This practical approach could allow pathologists to identify TNBC subtypes using standard laboratory equipment, making precision medicine accessible in routine practice.

Treatment Implications by Subtype

The four dominant TNBC subtypes—immunomodulatory, basal-like, mesenchymal, and luminal androgen receptor—have distinct features that guide treatment selection. Table 2 of the original review summarizes these differences:

Immunomodulatory (IM) Subtype

• Surrogate markers: High TIL/CD8, AR-negative, FoxC1-negative
• Immune environment: "Inflamed" tumour microenvironment
• Chemotherapy response: High (+++)
• HRD score: High
• Key pathways: High chromosome instability, elevated cell-cycle and DNA repair genes, activated immune signalling
• Potential treatments: Immune checkpoint blockade (drugs that release the immune system's brakes on cancer)

Basal-Like (BL) Subtype

• Surrogate markers: FoxC1-positive or strong P16, AR-negative
• Immune environment: Stromal or margin-restricted
• Chemotherapy response: High (+++)
• HRD score: High
• Key pathways: High chromosome instability, elevated cell-cycle and DNA repair genes
• Potential treatments: Platinum-based drugs (like carboplatin and cisplatin) and PARP inhibitors (which exploit DNA repair weaknesses)

Mesenchymal (MES) Subtype

• Surrogate markers: DCLK1-positive, AR-negative, FoxC1-negative
• Immune environment: Margin-restricted or "desert" (few immune cells)
• Chemotherapy response: Moderate (++)
• HRD score: Intermediate
• Key pathways: Intermediate chromosome instability, elevated EMT pathways, deregulated epigenetic pathways
• Potential treatments: Targeting stem cell pathways; EZH2 inhibitor combined with chemotherapy (to restore immune recognition)

Luminal Androgen Receptor (LAR) Subtype

• Surrogate markers: AR-positive
• Immune environment: Margin-restricted or desert
• Chemotherapy response: Low (+)—this subtype is the most chemotherapy-resistant
• HRD score: Low
• Key pathways: Low chromosome instability, AR signalling, intact RB1, enriched PIK3CA and ERBB2 mutations
• Potential treatments: HER2 inhibitors or antibody–drug conjugates; CDK4/6 inhibitors (which block cell division); AR inhibitors combined with PI3K/mTOR inhibitors

These subtype-specific strategies represent a fundamental shift from treating all TNBCs the same way to matching the treatment to the tumour's biology.

Clinical Implications: What This Means for Patients

The most important message for patients is that TNBC is not a single disease. A patient diagnosed with TNBC today should understand that their tumour has unique features—its microscopic appearance, its gene expression profile, its immune environment, and its genetic mutations—that influence how it will behave and how it should be treated.

Some practical implications include:

• Better prognostication: Low-grade histological variants generally have a favourable prognosis, and BLIA/immunomodulatory subtypes have better outcomes. Recognizing these early could help avoid overtreatment.
• Smarter chemotherapy choices: Basal-like tumours respond well to chemotherapy (+++), while LAR tumours respond poorly (+). This knowledge can guide the intensity and type of chemotherapy.
• Targeted therapy opportunities: Patients with LAR tumours might benefit from AR inhibitors, CDK4/6 inhibitors, or PI3K/mTOR inhibitors. Patients with HRD-high basal-like tumours might be candidates for PARP inhibitors or platinum chemotherapy.
• Immunotherapy guidance: The immunomodulatory subtype, with its inflamed tumour microenvironment and high TIL/CD8, may respond best to immune checkpoint blockade.
• Ethnic considerations: Subtype distribution varies by ethnicity—Asian patients have more LAR and fewer BLIS subtypes—which may influence treatment approaches in different populations.

The authors note that while the transcriptional heterogeneity of TNBC is well established, accurately assigning individual tumours to subtypes is not always reproducible. The development of a consensus signature for TNBC subtyping remains challenging, with issues such as mixed subtypes within a single tumour and transition states between subtypes (particularly BL1 and MES).

Limitations: What This Review Couldn't Prove

As a review article, this paper synthesizes existing research rather than presenting a new clinical trial. Several limitations should be noted:

• Subtyping reproducibility: When the same clustering strategy was applied to different datasets (TCGA and METABRIC), only five TNBC groups were found instead of six, and BL2 reproducibility was questionable. This means the classification systems are still being refined.
• Intratumoural heterogeneity: An individual tumour can contain mixed subtypes, particularly BL1 and MES, and single-cell studies suggest transition states between them. This complicates treatment decisions based on a single biopsy.
• Surrogate marker accuracy: While IHC surrogates like the AR/CD8/FOXC1/DCLK1 schema show good agreement (especially for LAR, kappa = 0.821), the agreement is not perfect—the lowest was in MES. IHC markers like FOXC1 (75% sensitivity) and SOX10 (70% accuracy) miss a meaningful proportion of cases.
• Prognostic value: The six-subtype TNBCtype classification's prognostic value was not consistently observed across studies, highlighting the need for further validation.
• Confounded gene profiles: Early subtype definitions (IM and MSL) were partly derived from tumour-infiltrating lymphocytes and stromal cells rather than tumour cells alone, which required later refinement.

Recommendations for Patients

While this is a scientific review rather than a patient guideline, its findings suggest several practical steps for patients and their families:

1. Ask about your tumour's specific characteristics. In addition to knowing that your cancer is triple-negative, ask your doctor whether your pathology report includes information about histological subtype (e.g., apocrine, metaplastic, adenoid cystic) or molecular subtyping.
2. Discuss biomarker testing. Ask whether your tumour has been tested for key markers like androgen receptor (AR), CD8, FOXC1, DCLK1, PD-L1, or BRCA mutations. These results can guide treatment options, including immunotherapy, PARP inhibitors, or AR-targeted therapy.
3. Understand the role of chemotherapy. Chemotherapy remains the backbone of TNBC treatment, and most TNBC subtypes respond to it. However, the response varies by subtype—LAR tumours tend to respond less, which may prompt discussion of alternative or additional strategies.
4. Explore clinical trials. Because TNBC subtyping is an active area of research, clinical trials testing subtype-specific treatments (including EZH2 inhibitors, AR inhibitors, CDK4/6 inhibitors, and antibody–drug conjugates) may be available. Ask your oncologist about relevant trials.
5. Consider genetic counselling. More than half of TNBCs carry the homologous recombination deficiency (HRD) signature, and germline BRCA1/2 mutations are found in a subset. Genetic testing can identify inherited risk and open the door to PARP inhibitor therapy.
6. Remember the good news. Not all TNBCs are aggressive. Low-grade variants like adenoid cystic carcinoma and secretory carcinoma generally have a favourable prognosis, and the immune-activated subtype has the best outcomes. A TNBC diagnosis does not automatically mean a poor outcome.

The authors conclude that recognizing TNBC's heterogeneity—from histology to molecular subtypes to the immune microenvironment—allows not only improved prognostication but also better treatment decisions. This is precision medicine in action: moving from treating the disease name to treating the individual tumour.

Frequently Asked Questions

What is triple-negative breast cancer?

Triple-negative breast cancer (TNBC) is a breast cancer that does not produce estrogen receptors, progesterone receptors, or HER2. It accounts for 10–15% of all breast cancers and is often aggressive, tending to be higher grade and larger at diagnosis. Younger patients are affected more often than with other breast cancer subtypes.

Why don't hormonal therapy or anti-HER2 drugs work for TNBC?

Because TNBC cells lack the three receptors that these targeted treatments rely on. Hormonal therapy needs estrogen or progesterone receptors, and anti-HER2 drugs need HER2. Since TNBC has none of these, chemotherapy has long been the main systemic treatment, though some new targeted and immune-based therapies are now being used.

What are the four main molecular subtypes of TNBC?

Based on tumor-cell gene expression, TNBC is often divided into four subtypes: basal-like 1 (BL1), basal-like 2 (BL2), mesenchymal (MES), and luminal androgen receptor (LAR). Another similar classification names them LAR, mesenchymal, basal-like immunosuppressed, and basal-like immune-activated. Each subtype has different genetic features and treatment implications.

Are all triple-negative breast cancers the same?

No. TNBC is a diverse group of diseases with different microscopic appearances, gene expression patterns, and immune profiles. Some low-grade variants, such as adenoid cystic carcinoma and secretory carcinoma, generally have a favorable prognosis. Other subtypes are more aggressive. Recognizing this heterogeneity helps doctors tailor treatment to each tumor's biology.

How does knowing my TNBC subtype affect treatment?

Different subtypes respond differently. Basal-like tumors usually respond well to chemotherapy, while luminal androgen receptor (LAR) tumors respond poorly. LAR tumors may benefit from AR inhibitors, CDK4/6 inhibitors, or PI3K/mTOR inhibitors. Immune-activated subtypes may respond to immune checkpoint blockade. Testing for markers like AR, CD8, FOXC1, or BRCA mutations can guide these choices.

What biomarker tests might my doctor consider for TNBC?

Doctors might test for androgen receptor (AR), CD8, FOXC1, DCLK1, PD-L1, or BRCA mutations. These can help identify which subtype your tumor belongs to and whether you might benefit from immunotherapy, PARP inhibitors, or AR-targeted therapy. Genetic testing can also reveal inherited BRCA1/2 mutations, which are present in a subset of TNBC patients.

Is a triple-negative breast cancer diagnosis always a poor prognosis?

No. Not all TNBCs are aggressive. Low-grade variants like adenoid cystic carcinoma and secretory carcinoma generally have a favorable prognosis. The immune-activated subtype also has better outcomes. Even among more common subtypes, many patients respond well to chemotherapy initially. A TNBC diagnosis does not automatically mean a poor outcome, and subtype testing helps refine prognosis.

Can a second opinion change my treatment plan for triple-negative breast cancer?

Yes. Triple-negative breast cancer is not one disease but a group of subtypes with different biology. Treatment response depends on the subtype: basal-like tumours respond well to chemotherapy, whereas luminal androgen receptor (LAR) tumours respond poorly. Immunomodulatory tumours may benefit from immunotherapy, and tumours with homologous recombination deficiency may respond to PARP inhibitors or platinum drugs. A second opinion can review your pathology for histological variant and molecular markers such as AR, CD8, FOXC1, DCLK1, and BRCA mutations, which may change the recommended treatment. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

This patient-friendly article is based on the following peer-reviewed research:

• Original title: "Update on triple-negative breast cancers – highlighting subtyping update and treatment implication"
• Authors: Julia Y. Tsang and Gary M. Tse
• Journal: Histopathology, Volume 82, pages 17–35 (2023)
• DOI: 10.1111/his.14784
• Institution: Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong

This article is a review (synthesis) of previously published research, not a new clinical study. It was translated into patient-friendly language to help patients and caregivers understand the latest science on triple-negative breast cancer subtyping and its treatment implications.